Disclosures for "A systematic review and meta-analysis of extended interval dosing (EID) vs. standard-interval dosing (SID) of Natalizumab for multiple sclerosis patients.")
-
Mr. Rabea has nothing to disclose.
-
Dr. Belal has nothing to disclose.
-
Dr. Nourelden has nothing to disclose.
-
Mr. El-banna has nothing to disclose.
-
Mr. Khalifa has nothing to disclose.
-
Dr. Mahmoud has nothing to disclose.
-
Mohamed Sayed Zaazouee has nothing to disclose.